Avantor, Inc. (NYSE:AVTR), a life sciences tools and services provider, faces significant headwinds. Two major investment firms downgraded the stock in late 2025 following a weak Q3 performance.
Raymond James and Barclays lowered their outlook after the company missed revenue and margin expectations. The stock has fallen over 43% in the past year, trading at $7.60 near its 52-week low.
Both segments, Bioproduction and Lab Solutions, underperformed due to competitive pressures, budget constraints in academic and government markets, and operational issues. Gross margins fell more than 220 basis points below expectations.
Management initiated a strategic review but refrained from providing specific near-term targets. The company's net debt of $3.6 billion against a market cap of $5.19 billion limits financial flexibility.
